Pronóstico del mercado de enfermedades cardiometabólicas de Asia Pacífico hasta 2028: impacto de COVID-19 y análisis regional por tipo (enfermedad cardiovascular (ECV), diabetes tipo 2, hipertensión y obesidad), tratamiento (inhibidores de la ECA, diuréticos, glucófagos y otros), dosis ( tableta e inyección), vía de administración (oral e intravenosa), usuarios finales (hospitales, clínicas y entornos de atención domiciliaria) y canal de distribución (farmacia hospitalaria, farmacia minorista y farmacia en línea)

Introducción al mercado

La enfermedad cardiometabólica se caracteriza por un grupo de anomalías y síntomas que aumentan el riesgo de que las personas desarrollen enfermedades cardiovasculares. Hipertensión, obesidad, resistencia a la insulina, dislipidemia, perfil deficiente de colesterol (LDL) y tolerancia a la glucosa son algunos de los síntomas. Las personas que padecen síndrome cardiometabólico son propensas a otras enfermedades potencialmente mortales, como diabetes tipo 2, accidente cerebrovascular, enfermedad de las arterias coronarias (EAC), enfermedades cardiovasculares (CVD) y muchas otras.

Además, se espera que la creciente prevalencia de enfermedades cardiometabólicas impulse el crecimiento del mercado durante el período previsto. Sin embargo, el subdiagnóstico de las enfermedades cardiovasculares en los países de ingresos bajos y medianos (PIBM) limita el crecimiento del mercado de enfermedades cardiometabólicas de Asia Pacífico.

Las interrupciones en la cadena de suministro y la demanda masiva de Los tratamientos eficientes para la terapia de COVID-19 han puesto a la industria de la investigación sanitaria en una situación crucial en la región de Asia Pacífico. Se han tomado medidas prohibitivas para controlar la propagación de esta pandemia. La pandemia de COVID-19 ha afectado ampliamente a las economías de la región de Asia Pacífico. Países como India (31.769.132), Japón (956.407), China (93.289), Corea del Sur (203.926) se vieron afectados negativamente por la pandemia. La situación socioeconómica se vio gravemente afectada, aumentando la inflación negativa, el PIB y un aumento del desempleo regional. Recientemente, los pacientes con hipertensión y obesidad han aumentado en Japón. Estos pacientes tienen un riesgo excepcionalmente alto de sufrir una enfermedad grave por COVID-19 y, por lo tanto, necesitan una observación cuidadosa y un tratamiento intensivo. Comparable a la hipertensión, la definición de obesidad no es constante entre los estudios/países, lo que requiere consideración. Sin embargo, es fundamental tener en cuenta que el mecanismo terapéutico de los BCC contra la COVID-19 aún espera más investigaciones y ensayos clínicos controlados aleatorios.

Descripción general del mercado y Dinámica

Se prevé que el mercado de enfermedades cardiometabólicas de Asia Pacífico alcance los 28.953,2 millones de dólares en 2028, desde los 21.091,3 millones de dólares de 2021; Se prevé que crezca a una tasa compuesta anual del 4,6% de 2021 a 2028. Las enfermedades cardiometabólicas (EMC) son una de las principales causas de muerte en todo el mundo. Estas enfermedades son causadas principalmente por un estilo de vida poco saludable, la inactividad física, el tabaquismo y una dieta poco saludable. Las CMD incluyen enfermedades cardiovasculares (ECV), diabetes mellitus e insuficiencia renal crónica. La mayoría de las enfermedades cardiovasculares se pueden prevenir abordando los factores de riesgo conductuales, como el consumo de tabaco, las elecciones dietéticas poco saludables, la obesidad, la inactividad física y el consumo de alcohol. La diabetes es una de las enfermedades crónicas potencialmente mortales que no tiene cura funcional. Conduce a diversas complicaciones y aumenta el riesgo general de muerte prematura. Los ataques cardíacos, los accidentes cerebrovasculares, la insuficiencia renal, la amputación de piernas, la pérdida de la visión y el daño a los nervios son las principales complicaciones asociadas con la diabetes. Hay un aumento en el número de personas que padecen una o más CMD debido al aumento del tabaquismo, la falta de ejercicio, el consumo de alcohol y los hábitos alimentarios poco saludables. La creciente prevalencia de la obesidad está dando lugar a que la base de pacientes también sufra TMC. Con este rápido aumento en la prevalencia de CMD, la necesidad de tratamientos apropiados para las enfermedades cardiometabólicas se ha disparado, lo que ha resultado en un enorme crecimiento del mercado de enfermedades cardiometabólicas de Asia Pacífico.

< u>Segmentos de mercado clave

En términos de tipo, el segmento de enfermedades cardiovasculares representó la mayor proporción del mercado de enfermedades cardiometabólicas de Asia Pacífico en 2020 En términos de tratamiento, el segmento de inhibidores de la ECA representó la mayor participación del mercado de enfermedades cardiometabólicas de Asia Pacífico en 2020. En términos de dosis, el segmento de tabletas representó la mayor participación del mercado de enfermedades cardiometabólicas de Asia Pacífico en 2020. de vía de administración, el segmento oral representó la mayor participación del mercado de enfermedades cardiometabólicas de Asia Pacífico en 2020. En términos de usuario final, el segmento hospitalario representó la mayor participación del mercado de enfermedades cardiometabólicas de Asia Pacífico en 2020. Además, según En el canal de distribución, el segmento de farmacia hospitalaria tuvo la mayor participación de mercado en 2020.

Principales fuentes y empresas cotizadas

Algunas de las principales fuentes primarias y secundarias a las que se hace referencia para preparar este informe sobre el mercado de enfermedades cardiometabólicas en Asia Pacífico son los sitios web de las empresas, los informes anuales y los informes financieros. , documentos del gobierno nacional y base de datos estadísticos, entre otros. Las principales empresas que figuran en el informe son Eli Lilly and Company, Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Cardax Inc. y Kowa Company, Ltd.

Informe de razones para comprar

Comprender el panorama del mercado de enfermedades cardiometabólicas de Asia Pacífico e identificar segmentos de mercado que probablemente garanticen un fuerte retorno
Comprender el panorama del mercado en constante cambio y permanecer a la cabeza en la competencia
Planificar eficientemente fusiones, adquisiciones y acuerdos de asociación en el mercado de enfermedades cardiometabólicas de Asia Pacífico identificando segmentos con las ventas probables más prometedoras
Tomar decisiones comerciales informadas a partir de un análisis perspicaz y completo del desempeño del mercado de varios segmentos
Obtener pronósticos de ingresos del mercado de Asia Pacífico Mercado de enfermedades cardiometabólicas basado en varios segmentos para el período 2021-2028

SEGMENTACIÓN DEL MERCADO DE ENFERMEDADES CARDIOMETABÓLICAS DE ASIA PACÍFICO

Por Tipo

Enfermedad cardiovascular (ECV)
Diabetes tipo 2
Hipertensión
Obesidad

Por tratamiento

Inhibidores de la ECA
Diuréticos
Glucófago
Otros

Por dosis

Tableta
Inyección

Por vía de administración

Oral
Intravenoso

Por usuarios finales

Hospital
Clínica
Entornos de atención domiciliaria ;

Por canal de distribución

Farmacia hospitalaria
Farmacia minorista
Farmacia en línea

Por país

Empresas mencionadas

1. Introduction 21

1.1 Scope of the Study. 21

1.2 The Insight Partners Research Report Guidance. 21

1.3 Market Segmentation. 23

1.3.7 Asia Pacific Cardiometabolic Diseases market – By Country. 25

2. Asia Pacific Cardiometabolic Diseases Market – Key Takeaways 26

3. Research Methodology 31

3.1 Coverage. 33

3.2 Secondary Research. 33

3.3 Primary Research. 34

4. Asia Pacific Cardiometabolic Diseases Market – Market Landscape 35

4.1 Overview.. 35

4.2 PEST Analysis. 36

4.3 Expert Opinions. 37

5. Asia Pacific Cardiometabolic Diseases Market – Key Market Dynamics 38

5.1 Market Drivers. 38

5.1.1 Increasing Prevalence of Cardiometabolic Diseases. 38

5.1.2 Innovation in Cardiometabolic Diseases Therapeutics. 38

5.2 Market Restraints. 39

5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs) 39

5.3 Market Opportunities. 40

5.3.1 Technological Advancements in CMD Diagnosis. 40

5.4 Future Trends. 40

5.4.1 Personalized Treatment for CMDs. 40

5.5 Impact Analysis. 41

6. Asia Pacific Cardiometabolic Diseases Market – Regional Analysis 42

6.1 Asia Pacific Cardiometabolic Diseases Market Revenue Forecast And Analysis. 42

7. Asia Pacific Cardiometabolic Diseases Market Analysis – By Type 44

7.1 Overview.. 44

7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44

7.3 Cardiovascular Disease (CVD) 45

7.3.1 Overview.. 45

7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 46

7.4 Hypertension. 47

7.4.1 Overview.. 47

7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 47

7.5 Type 2 Diabetes. 48

7.5.1 Overview.. 48

7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 48

7.6 Obesity. 50

7.6.1 Overview.. 50

7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 50

8. Asia Pacific Cardiometabolic Diseases Market Analysis – By Treatment 52

8.1 Overview.. 52

8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52

8.3 ACE inhibitors. 53

8.3.1 Overview.. 53

8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn) 53

8.4 Diuretics. 55

8.4.1 Overview.. 55

8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 55

8.5 Glucophage. 56

8.5.1 Overview.. 56

8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 56

8.6 Others. 57

8.6.1 Overview.. 57

8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 57

9. Asia Pacific Cardiometabolic Diseases Market Analysis – By Dosage 58

9.1 Overview.. 58

9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58

9.3 Tablet 59

9.3.1 Overview.. 59

9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 59

9.4 Injection. 60

9.4.1 Overview.. 60

9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 60

10. Asia Pacific Cardiometabolic Diseases Market Analysis – By Route of Administration 61

10.1 Overview.. 61

10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61

10.3 Oral 62

10.3.1 Overview.. 62

10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn) 62

10.4 Intravenous. 64

10.4.1 Overview.. 64

10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn) 64

11. Asia Pacific Cardiometabolic Diseases Market Analysis – By End User 66

11.1 Overview.. 66

11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66

11.3 Clinic. 67

11.3.1 Overview.. 67

11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn) 67

11.4 Hospital 68

11.4.1 Overview.. 68

11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn) 68

11.5 Homecare Settings. 70

11.5.1 Overview.. 70

11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn) 70

12. Asia Pacific Cardiometabolic Diseases Market Analysis – By Distribution Channel 72

12.1 Overview.. 72

12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72

12.3 Hospital Pharmacy. 73

12.3.1 Overview.. 73

12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 73

12.4 Retail Pharmacy. 74

12.4.1 Overview.. 74

12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 74

12.5 Online Pharmacy. 76

12.5.1 Overview.. 76

12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 76

13. Asia Pacific Cardiometabolic Diseases Market – Geographic Analysis 78

13.1 Asia Pacific: Cardiometabolic Diseases Market 78

13.1.1 Overview.. 78

13.1.2 Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 80

13.1.3 Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81

13.1.4 Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 81

13.1.5 Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82

13.1.6 Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82

13.1.7 Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83

13.1.8 Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83

13.1.9 Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84

13.1.9.1 China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 85

13.1.9.1.1 China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86

13.1.10 China: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86

13.1.11 China: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87

13.1.12 China: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87

13.1.13 China: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88

13.1.14 China: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88

13.1.15 China: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89

13.1.15.1 Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90

13.1.15.1.1 Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90

13.1.16 Japan: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91

13.1.17 Japan: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92

13.1.18 Japan: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92

13.1.19 Japan: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93

13.1.20 Japan: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93

13.1.21 Japan: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94

13.1.21.1 India: Cardiometabolic Diseases Market - Revenue and Forecasts to 2028 (USD Million) 95

13.1.21.1.1 India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96

13.1.22 India: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97

13.1.23 India: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97

13.1.24 India: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98

13.1.25 India: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98

13.1.26 India: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99

13.1.27 India: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99

13.1.27.1 South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100

13.1.27.1.1 South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100

13.1.28 South Korea: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101

13.1.29 South Korea: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102

13.1.30 South Korea: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102

13.1.31 South Korea: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103

13.1.32 South Korea: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103

13.1.33 South Korea: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104

13.1.33.1 Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105

13.1.33.1.1 Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105

13.1.34 Australia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106

13.1.35 Australia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107

13.1.36 Australia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107

13.1.37 Australia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108

13.1.38 Australia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108

13.1.39 Australia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109

13.1.39.1 Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110

13.1.39.1.1 Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110

13.1.40 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111

13.1.41 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112

13.1.42 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112

13.1.43 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113

13.1.44 Rest of Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113

13.1.45 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114

14. Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market 115

14.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic. 115

15. Asia Pacific Cardiometabolic Diseases Market – Industry Landscape 117

15.1 Overview.. 117

15.2 Growth Strategies in the Cardiometabolic Diseases Market (%) 118

15.3 Organic Developments. 119

15.3.1 Overview.. 119

15.4 Inorganic Developments. 122

15.4.1 Overview.. 122

16. Company Profiles 124

16.1 Eli Lilly and Company. 124

16.1.1 Key Facts. 124

16.1.2 Business Description. 124

16.1.3 Products and Services. 125

16.1.4 Financial Overview.. 127

16.1.5 SWOT Analysis. 130

16.1.6 Key Developments. 131

16.2 Bayer AG.. 134

16.2.1 Key Facts. 134

16.2.2 Business Description. 134

16.2.3 Products and Services. 135

16.2.4 Financial Overview.. 135

16.2.5 SWOT Analysis. 138

16.2.6 Key Developments. 139

16.3 Novartis AG.. 141

16.3.1 Key Facts. 141

16.3.2 Business Description. 141

16.3.3 Products and Services. 142

16.3.4 Financial Overview.. 143

16.3.5 SWOT Analysis. 146

16.3.6 Key Developments. 147

16.4 Boehringer Ingelheim International GmbH.. 148

16.4.1 Key Facts. 148

16.4.2 Business Description. 148

16.4.3 Products and Services. 149

16.4.4 Financial Overview.. 150

16.4.5 SWOT Analysis. 154

16.4.6 Key Developments. 155

16.5 Novo Nordisk A/S. 157

16.5.1 Key Facts. 157

16.5.2 Business Description. 157

16.5.3 Products and Services. 158

16.5.4 Financial Overview.. 159

16.5.5 SWOT Analysis. 162

16.5.6 Key Developments. 163

16.6 AstraZeneca. 165

16.6.1 Key Facts. 165

16.6.2 Business Description. 165

16.6.3 Products and Services. 166

16.6.4 Financial Overview.. 167

16.6.5 SWOT Analysis. 170

16.6.6 Key Developments. 171

16.7 Cardax, Inc. 173

16.7.1 Key Facts. 173

16.7.2 Business Description. 173

16.7.3 Products and Services. 174

16.7.4 Financial Overview.. 174

16.7.5 SWOT Analysis. 177

16.7.6 Key Developments. 177

16.8 Kowa Company, Ltd. 178

16.8.1 Key Facts. 178

16.8.2 Business Description. 178

16.8.3 Products and Services. 179

16.8.4 Financial Overview.. 179

16.8.5 SWOT Analysis. 180

16.8.6 Key Developments. 181

17. Appendix 182

17.1 About The Insight Partners. 182

17.2 Glossary of Terms. 183

LIST OF TABLES

Table 1. Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81

Table 2. Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 81

Table 3. Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82

Table 4. Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82

Table 5. Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83

Table 6. Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83

Table 7. China Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86

Table 8. China Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87

Table 9. China Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87

Table 10. China Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88

Table 11. China Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88

Table 12. China Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89

Table 13. Japan Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91

Table 14. Japan Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92

Table 15. Japan Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92

Table 16. Japan Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93

Table 17. Japan Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93

Table 18. Japan Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94

Table 19. India Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97

Table 20. India Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97

Table 21. India Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98

Table 22. India Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98

Table 23. India Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99

Table 24. India Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99

Table 25. South Korea Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101

Table 26. South Korea Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102

Table 27. South Korea Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102

Table 28. South Korea Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103

Table 29. South Korea Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103

Table 30. South Korea Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104

Table 31. Australia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106

Table 32. Australia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107

Table 33. Australia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107

Table 34. Australia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108

Table 35. Australia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108

Table 36. Australia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109

Table 37. Rest of Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111

Table 38. Rest of Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112

Table 39. Rest of Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112

Table 40. Rest of Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113

Table 41. Rest of Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113

Table 42. Rest of Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114

Table 43. Organic Developments in the Cardiometabolic Diseases Market 119

Table 44. Inorganic Developments in the Cardiometabolic Diseases Market 123

Table 45. Glossary of Terms, Asia Pacific Cardiometabolic Diseases Market 183

LIST OF FIGURES

Figure 1. Asia Pacific Cardiometabolic Diseases Market Segmentation. 23

Figure 2. Asia Pacific Cardiometabolic Diseases Market Overview.. 26

Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Asia Pacific Cardiometabolic Diseases Market 27

Figure 4. Asia Pacific Cardiometabolic Diseases Market – Leading Country Markets (US$ Million) 28

Figure 5. Asia Pacific Cardiometabolic Diseases Market, Industry Landscape. 29

Figure 6. Asia Pacific PEST Analysis. 36

Figure 7. Asia Pacific Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints. 41

Figure 8. Asia Pacific Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028. 43

Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44

Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 46

Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 47

Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 49

Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 51

Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52

Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 54

Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 55

Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 56

Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 57

Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58

Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 59

Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 60

Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61

Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn) 63

Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn) 65

Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66

Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn) 67

Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn) 69

Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn) 71

Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72

Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 73

Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 75

Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 77

Figure 33. Asia Pacific: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million) 79

Figure 34. Asia Pacific Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million) 80

Figure 35. Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84

Figure 36. China Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86

Figure 37. Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 91

Figure 38. India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96

Figure 39. South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 101

Figure 40. Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 106

Figure 41. Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 111

Figure 42. Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market 116

Figure 43. Growth Strategies in the Cardiometabolic Diseases Market (%) 118

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific cardiometabolic diseases market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement
Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports

Report Name	Published Date
Asia Pacific Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and Software an..	May 2022
Asia Pacific Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, Engine, Elec..	May 2022
Asia Pacific Ground Engaging Tools Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Application (Excavators, Loaders, Bulldozers, an..	May 2022

Purchase Options

Single User License

$3000

$1800

Site License

$4000

$2400

Enterprise License

$5000